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ﬁxation which reduces the level of opsonins. It can co-opt
host proteases to destroy opsonins on the bacterial surface.
Several different pore-forming toxins are secreted, some of
which destroy neutrophils (alpha-toxin and Panton Valen-
tine Leucocidin). If taken up by phagocytic cells S.aureus
can resist intracellular killing mechanisms such as lysozyme,
free oxygen radicals and antimicrobial peptides. S.aureus
can secrete proteins called superantigens which trigger the
activation of T cells in a manner that lacks the speciﬁcity of
antigen presentation. This causes depletion of immune cells
and the failure to mount a robust response with immunolog-
ical memory and may help explain the recurrent nature of
infections. This presentation will review current knowledge
of the phenomena of colopnization and disease pathogen-
esis gathered from studies with many strains of S.aureus.
Reference will be made to CA-MRSA where appropriate.
doi:10.1016/j.ijid.2008.05.123
52.004
Clinical Aspects of the Community-Acquired MRSA
Epidemic
H. Chambers
University of California San Francisco, San Francisco, CA,
USA
Prevalence of methicillin-resistant Staphylococcus
aureus(MRSA) in the community is high and rising both
in the United States and in other countries. USA300 and
USA400, are the predominant community-associated MRSA
(CA-MRSA) clones circulating in US communities. Enhanced
transmissibility and ﬁtness, and hypervirulence characterize
and probably drive emergence of MRSA in the community.
The burden of disease caused by MRSA in the community
exceeds that occurring in hospitals. In addition, community
strains of MRSA are now a major cause of hospital-onset
infections. Identiﬁcation of multiple-drug resistant vari-
ants of community MRSA strains is of particular concern.
Emergence of CA-MRSA has a profound impact on choice of
therapy for treatment of all staphylococcal infections. For
those treated as out-patients, clinicians must increasingly
rely on second line agents, often in the absence of good data
supporting their effectiveness. For hospitalized patients, an
inevitable consequence is even greater use of vancomycin.
This will increase the already considerable pressure for
selection of vancomycin non-susceptible strains. Use of
vancomycin will likely be accompanied by a higher rate of
treatment failure. Several alternative drugs are available
for treatment of MRSA, but none of these has yet been
shown to be superior to vancomycin. The search for new
approaches to prevention and treatment of staphylococcal
infections has never been more important.
doi:10.1016/j.ijid.2008.05.124
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verview Abstract for the Symposium: Partnering in R&D
o develop new drugs for the most neglected diseases
escription: Tropical diseases such as chloroquine-resistant
alaria, leishmaniasis, lymphatic ﬁlariasis, Chagas disease,
uman African trypanosomiasis (HAT), dengue fever, and
chistosomiasis continue to cause signiﬁcant morbidity and
ortality worldwide. With few new treatments that tend to
e unaffordable and poorly adapted to the ﬁeld, physicians
re forced to use old tropical medicines that are increas-
ngly ineffective due to inevitable drug resistance. Together
ith tuberculosis and HIV/AIDS, these disabling and/or life-
hreatening diseases represent an enduring unmet medical
eed and are collectively called ‘‘neglected diseases’’.
Of the 1,556 new drugs approved between 1975 and 2004,
nly 21 (1.3%) were speciﬁcally developed for tropical dis-
ases and tuberculosis, even though these diseases account
or 11.4% of the global disease burden. With exponential
rogress made in the basic knowledge of many infectious
iseases, it is ironic that the drugs currently used to treat
inetoplastid diseases were discovered decades ago. With
ew exceptions, the wealth of basic research knowledge of
hese parasites is not being translated into practical appli-
ations.
Although the R&D landscape has signiﬁcantly changed for
eglected diseases since 2000, the need remains for new
eld-adapted drugs for the kinetoplastid diseases. Founded
n 2003 to address the needs of patients with these most
eglected diseases, DNDi (Drugs for Neglected Diseases
nitiative) is a collaborative, patients’ needs-driven, not-
or-proﬁt drug R&D organization that is currently developing
ew treatments against sleeping sickness (human African
rypanosomiasis, HAT), visceral leishmaniasis (VL), Chagas
isease, and malaria.
The only way to improve control is to develop innovative
ew drugs and diagnostics and ensure they are available to
atients. This symposium aims to review the opportunities
nd challenges ahead in the different phases of research and
evelopment of new drugs for the most neglected diseases.
oi:10.1016/j.ijid.2008.05.125
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he Epidemiology of XDR TB in KwaZulu Natal South
frica: A New name or a New Problem
. Rustomjee ∗, A. Pym
Medical Research Council, Durban, South Africa
ntroduction: The description of the AIDS-related ‘‘Tugela
erry’’ Outbreak (TFO) of XDR TB in KwaZulu Natal focused
nternational attention on this province of South Africa as
n epicenter of an XDR TB epidemic of unknown proportion.
imilarly the global burden of TB drug-resistance, particu-
arly in countries with the highest incidence of HIV and TB is
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or the most part unknown. Of >100 countries that are not
apacitated to report TB resistance surveillance to WHO,
he majority reside in Africa. Global estimates are there-
ore extrapolated from different sources. The South African
DR/XDR TB burden is similarly estimated and for the most
art incomplete.
Discussion: An MDR TB survey of 2001 (MRC) estimated
he burden of MDR TB at levels between 1—3% with isolated
otspots. It was not designed to estimate XDR TB and was
classic ‘‘point prevalence’’ study that sampled from lim-
ted sites. KZN has been the only South African province
ith an expanded portfolio of routine susceptibility test-
ng for second-line drugs for all clinical isolates. ‘‘XDR’’ TB
as been documented since the late 1980’s and described in
reatment cohorts admitted for care. These results will be
resented. The TFO however recorded the highest cluster of
ndividual cases ever reported and exposed the limitations of
he current surveillance strategy that depended on periodic
ross-sectional surveys. As a result the MRC has embarked
n a rapid surveillance project identifying regions in the
rovince where XDR TB has been identiﬁed and targeting
hese settings for an in-patient and out-patient surveillance
roject.
Conclusions: The recommendation for a continuous,
xpanded, country-wide surveillance system is self-evident
f only to accurately inform the currently straining program-
atic management of drug-resistant TB and to provide the
arly warning signals of programmatic failure.
oi:10.1016/j.ijid.2008.05.126
4.002
DR-TB and XDR-TB in Asia
.E. Tupasi
Tropical Disease Foundation, Makati, Metro Manila,
hilippines
t is estimated that there were 149,615 (95% CLs,
14,780—217,921) incident MDR-TB cases in South East Asia
n 2006, 74% were in India while there were 152,694 (95%
Ls, 119,886—188,014) incident MDR-TB cases in the the
estern Paciﬁc region in 2006, with almost 85% of these
ases estimated to be in China. The proportion of XDR-TB
mong MDR-TB was highest in Japan, 30.9% followed by
4.6% in Hong Kong, SAR, 3.4% Philippines, 1.8% Korea, 1%
angladesh, and one case each in Vietnam, India, China and
epal. Population-based studies still have to be undertaken
o know the real magnitude of XDR-TB.
Extensively drug-resistant TB (XDR-TB) was ﬁrst
escribed in 2006 in 40 0f 49 countries studied with
% of MDR-TB isolates in the USA, 19% in Latvia and 15% in
orea among chronic cases. An outbreak of XDR-TB among
4 patients with a high prevalence of HIV in South Africa
eported in 2006 was characterized by high early mortality
f 98% and nosocomial transmission as well as transmision
n the community. This outbreak demonstrated that XDR-TB
s a threat to both TB and HIV control and emphasized
he need for infection control measures in health facility
ettings.
XDR, deﬁned as MDR-TB plus simultaneous resistance
o a ﬂuoroquinolone and an injectable second line anti-
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B drug, showed a cure rate that was signiﬁcantly low
nd a failure rate that was high compared to other MDR-
B patients in Latvia. To respond to this crisis, the WHO
lobal Response plan 2007—2008 emphasized the need to
trengthen basic DOTS and HIV programs, to scale up the pro-
rammatic management of MDR-TB, strengthen laboratory
ervices to support M(X)DR-TB diagnosis, expand M(X)DR-TB
urveillance to study trends and link with HIV, foster sound
nfection control, promote research on the development
f new diagnostics, drugs, and vaccines. Much like MDR-
B which is the consequence of poor DOTS, XDR-TB is the
onsequence of poor MDR-TB management.
oi:10.1016/j.ijid.2008.05.127
4.003
apid Diagnosis of MDR-TB in Low-resource Settings
.A.J. Moore
Wellcome Centre for Clinical Tropical Medicine Imperial
ollege London, London, United Kingdom
ccording to the inverse-care law, the highest standard of
are is least available to those most in need. Diagnosis of
rug-resistant TB has long been a clear example of this
henomenon. In recent years a number of candidate diag-
ostic tests have been developed in both the academic and
ommercial sectors which present potential opportunities
o aggressively address this inequity. This talk will discuss
ome of the currently available tools that are suitable for
esource-limited settings, their relative merits and draw-
acks, and a number of implementation challenges common
o all, drawing on experience from Peru.
oi:10.1016/j.ijid.2008.05.128
4.004
he Epidemiology of MDR-TB in Peru
. Gotuzzo
Instituto de Medicina Tropical ‘Alexander Von Humboldt’,
ima, Peru
B in Peru has been known since the pre-hispanic period in
ommies.
Peru and Haiti has had the highest rate of prevalence in
merica (>160× 105 per habitant), where more than 65% of
ases of pulmonary TB has sputum positive.
Recently, the WHO recognized the Peruvian DOT as one
f the best worldwide programs to have reach the two goals
f the DOT (Diagnosis in more than 90% cases and cure rate
ore than 90%) decreasing the incidence in 5-6% per year in
he last 10 years.
However, in the shanty towns of Lima, the rate of MDR-
B has being increasing in an important way, spreading to
rban parts of the big cities. Leaving in the North of Lima
as been noted as a risk factor, where the primary rate of
DR TB is 6%, while in the South of Lima is just 2%. The most
now risk factors are having an intra-domiciliary TB contact
nd a treatment failure in the second of month of the ﬁrst
ine therapy; others include Diabetes Mellitus, AIDS/HIV and
ealth care workers. Also, 10-15% of MDR TB cases are XDR.
